Acadia raises $200M in follow-on

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) raised $200 million through the sale of 6.1 million shares at $33 in a follow-on underwritten by JPMorgan, Goldman Sachs, BofA Merrill Lynch, Cowen, Piper Jaffray and Needham. Acadia proposed the offering after market hours on Monday, when it closed at $35.23.

In late May, Acadia launched Nuplazid pimavanserin to treat hallucinations and delusions associated with psychosis in Parkinson's disease patients. The small molecule serotonin (5-HT2A) receptor inverse agonist is the first FDA-approved drug for PD psychosis (PDP). ...